

CS/NSE/UFR/2011-12
January 31, 2012

TO
THE MANAGER
LISTING DEPARTMENT
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
EXCHANGE PLAZA, BANDRA KURLA COMPLEX
BANDRA (E), MUMBAI - 400 051

Dear Sir/Madam,

Stock Code - SUVEN-EQ

Sub: Notification of Un-audited Financial Results for the quarter ended 31/12/2011 -
Clause 41

.....

With reference to the above subject, we are forwarding here with Un-audited Financial Results of our Company for three months ended 31st December, 2011 in the prescribed proforma, as required under Clause-41 of the listing agreement as amended. The Board of Directors of our company has taken on record the enclosed Un-audited Financial Results for the 3rd Quarter in its meeting held on 31st January, 2012.

We do hereby here by inform that w.e.f. 31st December, 2011, Suven Nishtaa Pharma Pvt. Ltd., has become a wholly owned subsidiary company of Suven Life Sciences Limited.

Further the Board of Directors at their Meeting held on January 31, 2012 has given its consent for the amalgamation of the said wholly owned subsidiary - Suven Nishtaa Pharma Private Limited with the holding Company - Suven Life Sciences Limited, subject to the approval of the scheme by the Hon'ble High Court of Andhra Pradesh. Consequent to the above, there will be no issue of shares pursuant to the merger, since the Company which is being proposed to be merged with the holding Company is a wholly owned subsidiary.

Please find enclosed Press release of our company. We request you to take these Documents on your Records

Thanking You,

Yours faithfully,
For SUVEN LIFE SCIENCES LIMITED


K HANUMANTHA RAO
Company Secretary

Suven Life Sciences Limited

Regd. Office: Serene Chambers, Road # 5, Avenue 7, Banjara Hills, Hyderabad 500 034, INDIA
Tel: 91~40~2354 1142/ 3311, 3292 1695/ 96, Fax: 91~40~2354 1152
info@suven.com www.suven.com



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31st DECEMBER 2011

(₹ in lacs), except share data

Sl. No.	PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended
		31/12/2011	30/09/2011	31/12/2010	31/12/2011	31/12/2010	31/3/2011
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Sales & Services	4,872.27	4,812.88	3,206.48	14,158.98	10,533.18	15,104.22
	Less : Excise duty	8.57	8.50	11.11	27.62	54.42	60.84
	Net Income from Sales & Services	4,863.70	4,804.38	3,195.37	14,131.36	10,478.76	15,043.38
2	Expenditure						
	a) Decrease (Increase) in stock in trade	(879.48)	(92.73)	(398.64)	(982.83)	(24.10)	(53.43)
	b) Consumption of raw materials	2,125.68	1,678.55	1,404.30	5,658.34	3,703.56	5,549.85
	c) Purchase of traded goods	-	-	-	-	-	-
	d) Personnel cost	583.66	594.21	408.85	1,649.34	1,249.77	1,782.08
	e) Depreciation	138.27	140.02	137.64	417.01	408.39	544.55
	f) Other expenditure - Manufacturing Exps	736.75	585.70	523.87	1,876.52	1,473.02	2,082.72
	- Selling Exps	41.64	83.00	24.81	173.05	140.21	261.95
	- Administrative Exps	679.22	297.03	377.99	1,258.18	769.66	1,029.44
	- R & D Exps	858.01	877.31	780.68	2,483.14	2,347.61	3,114.35
	- Provision for MTM on Forward Contracts	660.83	541.86	-	1,202.69	-	-
	g) Total	4,944.58	4,704.95	3,259.50	13,735.44	10,068.12	14,311.51
3	Profit from operations before Other Income, Interest & Exceptional Items (1-2)	(80.88)	98.43	(64.13)	395.92	410.64	731.87
4	Other Income	156.28	162.28	6.14	338.84	42.92	125.74
5	Profit before Interest & Exceptional Items (3+4)	75.40	260.71	(57.99)	734.76	453.56	857.61
6	Interest	213.52	192.97	129.85	570.07	389.41	532.17
7	Profit after Interest but before Exceptional Items (5-6)	(138.12)	67.74	(187.84)	164.69	64.15	325.44
8	Exceptional Items	-	-	-	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7-8)	(138.12)	67.74	(187.84)	164.69	64.15	325.44
10	Tax Expenses	(267.57)	(188.38)	(299.81)	(556.97)	(625.73)	(714.50)
11	Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)	129.45	256.12	111.97	721.66	689.88	1,039.94
12	Extraordinary Items	-	-	-	-	-	-
13	Net Profit (+)/Loss(-) for the period (11-12)	129.45	256.12	111.97	721.66	689.88	1,039.94
14	Paid-up equity share capital (Face Value of the Share)	1,167.32 Re.1.00	1,167.32 Re.1.00	1,167.32 Re.1.00	1,167.32 Re.1.00	1,167.32 Re.1.00	1,167.32 Re.1.00
15	Reserves excluding revaluation Reserve Reserves as per balance sheet of previous accounting year	-	-	-	-	-	11,506.42
16	Earning Per Share (EPS)						
	a) Basic and diluted EPS before extra ordinary items	0.11	0.22	0.10	0.62	0.59	0.89
	b) Basic and diluted EPS after extra ordinary items to date and for the previous year (not annualised)	0.11	0.22	0.10	0.62	0.59	0.89
17	Public share holdings						
	- Number of shares	42,679,160	42,679,160	42,858,960	42,679,160	42,858,960	42,858,960
	- Percentage of Share holding	36.56%	36.56%	36.72%	36.56%	36.72%	36.72%
18	Promoters and promoter group Shareholding						
	a) Pledged / Encumbered - Number of shares	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of Shares (on promoter & promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of Shares (on total share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL
	b) Non-Encumbered - Number of shares	74,052,828	74,052,828	73,873,028	74,052,828	73,873,028	73,873,028
	- Percentage of Shares (on promoter & promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of Shares (on total share capital of the company)	63.44%	63.44%	63.28%	63.44%	63.28%	63.28%



SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED						
PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended
	31/12/2011	30/09/2011	31/12/2010	31/12/2011	31/12/2010	31/3/2011
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 SEGMENT REVENUE :-						
a) Manufacturing (GRAMS)	4,600.69	4,358.64	2,478.68	13,274.95	8,703.62	12,675.22
b) Services (DDDSS)	271.58	454.23	727.80	884.03	1,829.56	2,429.01
c) Research & Development	-	-	-	-	-	-
Net Sales from Operations	4,872.27	4,812.87	3,206.48	14,158.98	10,533.18	15,104.23
2 SEGMENT RESULTS :-						
Profit/(Loss) before tax and interest:						
a) Manufacturing (GRAMS)	1,959.14	1,512.59	591.55	4,799.04	2,405.03	3,494.25
b) Services (DDDSS)	111.12	279.78	425.94	459.45	870.93	1,063.51
c) Research & Development	(858.01)	(877.31)	(780.68)	(2,483.14)	(2,347.61)	(3,114.35)
TOTAL	1,212.25	915.06	236.81	2,775.35	928.35	1,443.41
Less: i) Interest	213.52	192.97	129.85	570.07	389.41	532.17
ii) Other Un-allocable exps net off un-allocable Income	1,136.85	654.35	294.80	2,040.59	474.79	585.80
Total Profit Before Tax	(138.12)	67.74	(187.84)	164.69	64.15	325.44
3 CAPITAL EMPLOYED						
(Segment Assets - Segment Liabilities)						
a) Manufacturing (GRAMS)	14,356.18	12,566.39	11,722.43	14,356.18	11,722.43	12,075.70
b) Services (DDDSS)	312.27	381.73	949.42	312.27	949.42	629.97
c) Research & Development	2,973.76	3,438.29	3,409.89	2,973.76	3,409.89	3,506.95
d) Net assets which are not segmented and used commonly	4,103.06	3,569.93	2,231.64	4,103.06	2,231.64	3,036.80
TOTAL	21,745.27	19,956.34	18,313.38	21,745.27	18,313.38	19,249.42

Notes:

- 1) The above un-audited results were approved and taken on record at the Board of Directors' meeting held on 31st, Jan' 2012
- 2) Status of investor grievance :- Opening bal : 01, Received : 30, Resolved : 31, Closing bal : Nil
- 3) Previous years figures have been regrouped / reclassified whenever necessary.
- 4) The limited review has been completed by the Statutory Auditors.
- 5) Provision for MTM Losses pertain to Forward Contracts entered for covering the future receivables in USD.

Place : Hyderabad
Date : 31/01/2012



For SUVEN LIFE SCIENCES LTD

VENKAT JASTI
Chairman & CEO

We Deliver



News Release

Suven's revenue up by 57% and EBIDTA up by 168% for 3rd Quarter ended 31st Dec'2011

HYDERABAD, INDIA (31st Jan, 2012) - SUVEN LIFE SCIENCES LIMITED, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its un-audited financial results for the quarter ended 31st Dec 2011. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 31st Jan 2012 at Hyderabad.

Financial Highlights for the 3rd Quarter ended Dec' 2011:

Growth in revenue	Rs 501.99 mil vs. Rs 320.15 mil	- 56.79%
Growth in PAT	Rs 12.95 mil vs. Rs 11.20 mil	- 15.63%
Growth in EBIDTA	Rs 21.36 mil vs. Rs 7.96 mil	- 168.34%

*PAT for qtr ending Dec 2011 is after provision for MTM of Rs. 66.08 mil towards forward contracts due to exchange fluctuation.

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 85.8 mil (17.09% on revenue) for the quarter ended Dec' 2011.

9 months period ended 31st Dec, 2011, recorded a revenue growth of 37.53%, increase in PAT by 4.61% and increase in EBIDTA by 33.62%. Total R&D expenditure for the Nine ended Dec' 2011 stood at Rs. 248.31 mil (previous period Rs. 234.76 mil).

*PAT for Nine months ending Dec 2011 is after provision for MTM of Rs. 120.27 mil towards forward contracts due to exchange fluctuation

During the quarter there were major qualitative achievements with the grant of 4 product patents to Suven's drug discovery pipeline which consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;



CS/NSE/UFR/2011-12
January 31, 2012

TO
THE MANAGER
LISTING DEPARTMENT
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
EXCHANGE PLAZA, BANDRA KURLA COMPLEX
BANDRA (E), MUMBAI - 400 051

Dear Sir/Madam,

Stock Code - SUVEN-EQ

Sub: Limited Review Report for the Quarter ended 31st December, 2011


.....

With reference to above subject, please find enclosed herewith Limited Review Report of the Auditors of the Company on the quarterly Un-audited results declared by the company for the third quarter ended 31st December, 2011.

We request to take this document on your records

Thanking you,

Yours faithfully,
For SUVEN LIFE SCIENCES LIMITED



K. HANUMANTHA RAO
Company Secretary

Suven Life Sciences Limited

Regd. Office: Serene Chambers, Road # 5, Avenue 7, Banjara Hills, Hyderabad 500 034, INDIA

Tel: 91~40~2354 1142/ 3311, 3292 1695/ 96, Fax: 91~40~2354 1152

info@suven.com

www.suven.com



Ref No.LR/009/2011-12:

LIMITED AUDIT REVIEW REPORT

To

The National Stock Exchange Limited
Mumbai.

We have reviewed the accompanying statement of unaudited financial results of M/S. SUVEN LIFE SCIENCES LIMITED, having registered office at 8-2-334, 6th Floor, SDE Serene Chambers, Road No 7, Banjara Hills, Hyderabad – 34, for the period ended on 31.12.2011, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for KARVY & CO.,
Chartered Accountants
(Registration No.001757S)


(K. AJAY KUMAR)
P A R T N E R
M.No.21989



Place: Hyderabad
Date : 31.01.2012.